Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC)

被引：8

作者：

Tsurutani, J. ^{[1
]}

Jacot, W. ^{[2
]}

Yamashita, T. ^{[3
]}

Riaz, F. ^{[4
]}

Yerushalmi, R. ^{[5
]}

Im, S-A. ^{[6
]}

Niikura, N. ^{[7
]}

Halser-Strub, U. ^{[8
]}

Cortes, J. ^{[9
,10
]}

Wennstig, A-K. ^{[11
]}

Chae, Y. ^{[12
]}

Wang, X. ^{[13
]}

Li, W. ^{[14
]}

Simon, H. ^{[15
]}

Masci, G. ^{[16
]}

Tamburini, E. ^{[17
]}

Aguilar, C. Orbegoso ^{[18
]}

Tecson, K. ^{[19
]}

Yung, L. ^{[20
]}

Modi, S. ^{[21
]}

机构：

[1] Showa Univ Hosp, Adv Canc Translat Res Inst, Tokyo, Japan

[2] Inst Canc Montpellier, Med Oncol, Montpellier, France

[3] Kanagawa Canc Ctr, Breast Surg & Oncol, Yokohama, Kanagawa, Japan

[4] Stanford Sch Med, Med Oncol, Stanford, CA USA

[5] Tel Aviv Univ, Inst Oncol, Davidoff Ctr, Rabin Med Ctr, Petah Tiqwa, Israel

[6] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Internal Med, Seoul, South Korea

[7] Tokai Univ, Breast Oncol, Sch Med, Isehara, Kanagawa, Japan

[8] Kantonsspital St Gallen, Breast Ctr, St Gallen, Switzerland

[9] Int Breast Canc Ctr, Oncol, Pangaea Oncol, Quironsalud Grp, Madrid, Spain

[10] Int Breast Canc Ctr, Oncol, Pangaea Oncol, Quironsalud Grp, Barcelona, Spain

[11] Sundsvall Hosp, Oncol, Sundsvall, Sweden

[12] Kyungpook Natl Univ, Med Oncol, Chilgok Hosp, Daegu, South Korea

[13] Zhejiang Canc Hosp, Med Oncol, Canc Res Inst, Hangzhou, Peoples R China

[14] First Hosp Jilin Univ, Tumor Ctr, Changchun, Jilin, Peoples R China

[15] CHU Brest, Oncol, Hop Morvan, Inst Cancerol & Hematol, Brest, France

[16] Humanitas Clin Res Hosp Rozzano, Med Oncol, Rozzano, MI, Italy

[17] Pia Fdn Cardinale G Panico Hosp, Oncol & Palliat Care, Tricase, Italy

[18] Daiichi Sankyo France SAS, Global Oncol R&D, Rueil Malmaison, France

[19] Daiichi Sankyo Inc, Evidence Generat, Basking Ridge, NJ USA

[20] Daiichi Sankyo Inc, Global Oncol R&D, Basking Ridge, NJ USA

[21] Mem Sloan Kettering Canc Ctr, Med, New York, NY USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.565

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

388P

引用

页码：S342 / S343

页数：2

共 50 条

[21] Patient-reported outcomes (PROs) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC)
Curigliano, G.
Dunton, K.
Rosenlund, M.
Janek, M.
Cathcart, J.
Liu, Y.
Fasching, P. A.
Iwata, H.
ANNALS OF ONCOLOGY, 2022, 33 : S196 - S197
[22] Effects of trastuzumab deruxtecan (T-DXd) vs choice of chemotherapy (TPC) on patient-reported outcomes (PROs) in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer (mBC): Results from DESTINY-Breast06
Hu, X.
Curigliano, G.
Yonemori, K.
Bardia, A.
Barrios, C. H. E.
Sohn, J.
Levy, C.
Jacot, W.
Tsurutani, J.
Mezei, K.
de Climens, A. Roborel
Wu, X.
Begbie, N.
Mbanya, Z.
Dent, R. A.
ANNALS OF ONCOLOGY, 2024, 35 : 1214 - 1215
[23] Approval study DESTINY-Breast04 convinces in new category trastuzumab-deruxtecan: First targeted therapy for metastatic HER2-low breast cancer
Fessler, Beate
BREAST CARE, 2023, 18 (02)
[24] Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+metastatic breast cancer (mBC) from DESTINY-Breast-01,-02, and-03
Saura, Cristina
Cortes, Javier
Modi, Shanu
Kim, Sung-Bae
Hamilton, Erika P.
Hurvitz, Sara A.
Krop, Ian E.
Curigliano, Giuseppe
Iwata, Hiroji
Im, Seock-Ah
Herbolsheimer, Pia Maarit
Karnoub, Maha
Gambhire, Dhiraj
Egorov, Anton
Andre, Fabrice
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[25] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+advanced/metastatic breast cancer (mBC) with or without brain metastases (BM): DESTINYBreast-12 primary results
Lin, N.
Ciruelos, E. M.
Jerusalem, G.
Mueller, V.
Niikura, N.
Viale, G.
Bartsch, R.
Kurzeder, C.
Connolly, R.
Baron-Hay, S. E.
Cortes, M. Gion
Guarneri, V.
Bianchini, G.
Wildiers, H.
Escriva-de-Romani, S.
Prahladan, M.
Bridge, H.
Verma, S.
Harbeck, N.
ANNALS OF ONCOLOGY, 2024, 35 : 1211 - 1212
[26] Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)
Saura Manich, C.
Modi, S.
Krop, I.
Park, Y. H.
Kim, S-B.
Tamura, K.
Andre, F.
Iwata, H.
Ito, Y.
Tsurutani, J.
Sohn, J.
Lee, C.
Liu, Y.
Cathcart, J.
Singh, J.
Yamashita, T.
ANNALS OF ONCOLOGY, 2021, 32 : S485 - S486
[27] An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01,-02, and-03
Krop, Ian E.
Wildiers, Hans
Hurvitz, Sara A.
Cortes, Javier
Im, Seock-Ah
Iwata, Hiroji
Andre, Fabrice
Saura, Cristina
Modi, Shanu
Kim, Sung-Bae
Egorov, Anton
Mathias, Elton
Cathcart, Jillian
Cagnazzo, Antonio
Cheng, Yingkai
Park, Yeon Hee
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[28] Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer
Modi, Shanu
Saura, Cristina
Yamashita, Toshinari
Park, Yeon Hee
Kim, Sung-Bae
Tamura, Kenji
Andre, Fabrice
Iwata, Hiroji
Ito, Yoshinori
Tsurutani, Junji
Sohn, Joohyuk
Denduluri, Neelima
Perrin, Christophe
Aogi, Kenjiro
Tokunaga, Eriko
Im, Seock-Ah
Lee, Keun Seok
Hurvitz, Sara A.
Cortes, Javier
Lee, Caleb
Liu, Yali
Zhang, Lin
Shahidi, Javad
Yver, Antoine
Baselga, Jose
Krop, Ian E.
CANCER RESEARCH, 2021, 81 (04)
[29] Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis
Jerusalem, Guy
Park, Yeon Hee
Yamashita, Toshinari
Hurvitz, Sara A.
Modi, Shanu
Andre, Fabrice
Krop, Ian E.
Farre, Xavier Gonzalez
You, Benoit
Saura, Cristina
Kim, Sung-Bae
Osborne, Cynthia R.
Murthy, Rashmi K.
Gianni, Lorenzo
Takano, Toshimi
Liu, Yali
Cathcart, Jillian
Lee, Caleb
Perrin, Christophe
CANCER DISCOVERY, 2022, 12 (12) : 2754 - 2762
[30] Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.
Hamilton, Erika P.
Petry Helena, Vanessa Bragaia
Yeo, Bragaia Winnie
Kim, Sung-Bae
Bianchini, Giampaolo
Yamashita, Toshinari
Yonemori, Kan
Inoue, Kenichi
Curigliano, Giuseppe
Hurvitz, Sara A.
Cortes, Javier
Iwata, Hiroji
Cathcart, Jillian
Liu, Yali
Lee, Caleb C.
Bako, Emarjola
Kim, Rachel
Im, Seock-Ah
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →